Open access · OA
via OpenAlex
Blood‐based biomarkers for Alzheimer's disease
Antoine Leuzy, Niklas Mattsson, Sebastian Palmqvist, Shorena Janelidze, Jeffrey L. Dage, Oskar Hansson
EMBO Molecular Medicine · 2021 · ▲ 351 citations
Abstract
Neurodegenerative disorders such as Alzheimer's disease (AD) represent a mounting public health challenge. As these diseases are difficult to diagnose clinically, biomarkers of underlying pathophysiology are playing an ever-increasing role in research, clinical trials, and in the clinical work-up of patients. Though cerebrospinal fluid (CSF) and positron emission tomography (PET)-based measures are available, their use is not widespread due to limitations, including high costs and perceived invasiveness. As a result of rapid advances in the development of ultra-sensitive assays, the levels of pathological brain- and AD-related proteins can now be measured in blood, with recent work showing promising results. Plasma P-tau appears to be the best candidate marker during symptomatic AD (i.e., prodromal AD and AD dementia) and preclinical AD when combined with Aβ42/Aβ40. Though not AD-specific, blood NfL appears promising for the detection of neurodegeneration and could potentially be used to detect the effects of disease-modifying therapies. This review provides an overview of the progress achieved thus far using AD blood-based biomarkers, highlighting key areas of application and unmet challenges.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.15252/emmm.202114408
- Canonical
- link ↗
- Fetched
- 2026-10-17 MST
Cite this
APA
Leuzy, A., Mattsson, N., Palmqvist, S., Janelidze, S., Dage, J.L., & Hansson, O. (2021). Blood‐based biomarkers for Alzheimer's disease. <em>EMBO Molecular Medicine</em>. https://doi.org/10.15252/emmm.202114408
Vancouver
Leuzy A, Mattsson N, Palmqvist S, Janelidze S, Dage JL, Hansson O. Blood‐based biomarkers for Alzheimer's disease. EMBO Molecular Medicine. 2021. doi:10.15252/emmm.202114408.
BibTeX
@article{antoine2021Bloodb,
title = {Blood‐based biomarkers for Alzheimer's disease},
author = {Antoine Leuzy and Niklas Mattsson and Sebastian Palmqvist and Shorena Janelidze and Jeffrey L. Dage and Oskar Hansson},
journal = {EMBO Molecular Medicine},
year = {2021},
doi = {10.15252/emmm.202114408},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Ageing Research Reviews 2026
Open access · CC-BY
Blood-based biomarkers for Alzheimer's disease: Advances in early detection and monitoring of age-related neurodegeneration
Neurobiology of Disease 2014
Preprint · OA
Early detection of Alzheimer's disease using PiB and FDG PET
International Journal of Molecular Sciences 2024
Open access · CC-BY
Proteomic Markers of Aging and Longevity: A Systematic Review
Qatar Foundation Annual Research Conference (ARC) 2016
Citation only
Alpha-Synuclein Oligomers as a Biomarker Candidate for Parkinson's Disease and Disorders
University Hospital, Strasbourg, France 2010
Open access · US-GOV
Analysis of Clinical Data and Diagnosis in Any Person Requiring an Assay of Alzheimer Biomarkers in Cerebrospinal Fluid
Drug development research 2025
Open access · OA